# EDGAR Filing Document

**Accession Number:** 0001970632
**File Stem:** 0001493152-25-020068
**Filing Date:** 2025-10
**Character Count:** 7555
**Document Hash:** 8fe0cc4534eba77aa5fa5cc8ae22c24e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-020068.hdr.sgml**: 20251029

**ACCESSION NUMBER**: 0001493152-25-020068

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251029

**DATE AS OF CHANGE**: 20251029

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CytoMed Therapeutics Ltd
- **CENTRAL INDEX KEY:** 0001873093
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** U0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94045
- **FILM NUMBER:** 251430132

**BUSINESS ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544
- **BUSINESS PHONE:** 603824911

**MAIL ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CytoMed Therapeutics Pte. Ltd.
- **DATE OF NAME CHANGE:** 20210716
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Choo Chee Kong
- **CENTRAL INDEX KEY:** 0001970632

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** COMMONWEALTH LANE 08-22
- **CITY:** SINGAPORE
- **STATE:** U0
- **ZIP:** 149544

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**CytoMed Therapeutics Limited**

*(Name of Issuer)*

**Ordinary Shares**

*(Title of Class of Securities)*

**Y1R80M106**

*(CUSIP Number)*

**Choo Chee Kong**

#08-22 ONE COMMONWEALTH,<br>1 COMMONWEALTH LANE<br>Singapore U0 149544<br>65 6250 7738

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/29/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **Y1R80M106** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Choo Chee Kong** | Name of reporting person<br>**Choo Chee Kong** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**U0** | Citizenship or place of organization<br>**U0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**512436.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3773291.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**512436.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3773291.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2587746.00** | Aggregate amount beneficially owned by each reporting person<br>**2587746.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**22.05%** | Percent of class represented by amount in Row (11)<br>**22.05%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares

**(b) Name of Issuer:**
CytoMed Therapeutics Limited

**(c) Address of Issuer's Principal Executive Offices:**
#08-22 ONE COMMONWEALTH, 1 COMMONWEALTH LANE, Singapore, U0, 149544

**Item 4. Purpose of Transaction**

Mr. Choo Chee Kong has acquired all of the Ordinary Shares beneficially owned by him (1) in exchange for capital contributions to the Issuer or (2) through public purchases on the open market with his personal funds for investment purposes. The Reporting Person serves as Chairman of the Issuer and is a member of the board of directors of the Issuer and, as a result, may be asked to vote on or discuss matters related to items (a) through (j) of this Item 4 of Schedule 13D with representatives of the Issuer and others. Except as may be set forth herein, the Reporting Person has no current intention, plan or proposal with respect to items (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows:
the Reporting Person beneficially owns 2,587,746 Ordinary Shares, representing 22.05% of the Issuer's outstanding shares as of the date hereof.

This includes: (1) 2,075,310 Ordinary Shares held indirectly through Glorious Finance Limited ("Glorious Finance"), in which Mr. Choo Chee Kong owns a 55% stake. As such, he is deemed to beneficially own 55% of the 3,773,291 shares held by Glorious Finance, while disclaiming ownership of the remainder. These shares were issued in exchange for capital contributions; (2) 194,112 Ordinary Shares held by EP Capital Inc. ("EP Capital"), which Mr. Choo Chee Kong is deemed to beneficially own. These shares were issued in exchange for capital contributions; and (3) 318,324 Ordinary Shares held directly by Mr. Choo Chee Kong, acquired with personal funds. The calculation is based on 11,733,912 Ordinary Shares outstanding as of the date hereof.

**(b)**
Please refer to Items 7-13 of the Cover Page. The Reporting Person has sole voting and dispositive power over 512,436 Ordinary Shares, and shared voting and dispositive power over 3,773,291 Ordinary Shares.

**(c)**
From October 2, 2025 to October 28, 2025, the Reporting Person purchased an aggregate of 130,824 ordinary shares of the Issuer in open market transactions through a brokerage account. All such transactions were conducted in compliance with the Issuer's insider trading policy and Rule 10b-5 under the Securities Exchange Act of 1934, as amended.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The Reporting Person and the remaining shareholders of Glorious Finance Limited may be deemed to be acting as a "group" under Section 13(d)(3) as they share voting and dispositive power over the 3,773,291 Ordinary Shares of the Issuer. However, there is no formal agreement governing their voting or investment decisions.

Except as set forth herein, the Reporting Person has no contracts, arrangements, understandings, or relationships with respect to the Issuer's securities requiring disclosure under this Item 6.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Choo Chee Kong

**Signature:** /s/ Choo Chee Kong

**Name/Title:** Choo Chee Kong / Chairman and Director of CytoMed Therapeutics Limited

**Date:** 10/29/2025